PODD

Insulet is firing on all cylinders operationally. FY2025 revenue grew 30.7% to $2.71B (29.5% constant-currency), with Omnipod product revenue up 31.6% and international up 44.1% as Omnipod 5 launches scale globally. The MD&A confirms a 600,000+ active user base and a strategic pivot to attack the much larger Type 2 diabetes market with Omnipod 5 (FDA expanded indication received August 2024), while abandoning Omnipod GO. Gross margin expanded 180bps to 71.6% on manufacturing/supply-chain efficiencies and mix, operating income jumped 53.4% to $474M, and operating cash flow rose 32.3% to $569M. The balance sheet is healthier than headline: equity grew 25.1% to $1.52B, total liabilities fell 10.7%, retained earnings inflected to $287M, and management has hedged $460M of Term Loan B via April 2025 swaps — explicitly noting a 100bp move would be 'insignificant' to earnings.

The complication is the net income line: GAAP net income fell 40.9% to $247M and diluted EPS fell to $3.48 despite operating income up 53.4%. That divergence (combined with a -24.9% cash draw to $716M and capex up 53.4% to $192M) signals heavy reinvestment plus below-the-line items — investors should not anchor on the 44x P/E as a steady-state multiple. On 9.1% net margin and 16.3% ROE, the quality is real but not yet elite for the multiple.